MedTrace Logo

Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy

NCT04152434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2019-11-05

No results posted yet for this study

Summary

Treatment of chronic migraineurs who have failed more than 3 preventive drugs with Erenumab alone, to reduce frequency of monthly migraine days or as an add on therapy

Conditions

  • Refractory Chronic Migraine

Interventions

DRUG

Erenumab Auto-Injector

Assess synergy of add on medication to Erenumab

Sponsors & Collaborators

  • Clinique des Céphalées de Montréal

    lead OTHER

Principal Investigators

  • Guy P Boudreau, md · Clinique des Céphalées de Montréal

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-07-30
Completion
2019-08-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04152434 on ClinicalTrials.gov